DUBLIN–(BUSINESS WIRE)–The “Follicular Lymphoma – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering.
This Follicular lymphoma – Pipeline Insight, 2021 provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Follicular lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Follicular lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Follicular lymphoma.
Follicular lymphoma Emerging Drugs Chapters
This segment of the Follicular lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Follicular lymphoma Emerging Drugs
Pembrolizumab: Merck & Co
Pembrolizumab is a monoclnal antibody that binds to and blocks PD-1 located on lymphocytes. This receptor is generally responsible for preventing the immune system from attacking the body’s own tissues; it is a so-called immune checkpoint. Normally, the PD-1 receptor on activated T-cells binds to ligands PD-L1 or PD-L2 on other cells, deactivating a potential T-cell-mediated immune response against normal cells in the body. Currently, it is in phase II stage of development to treat Follicular lymphoma.
Mosunetuzumab: Genentech
Mosunetuzumab is an investigational CD20xCD3 T-cell engaging bispecific designed to target CD20 on the surface of B-cells and CD3 on the surface of T-cells. This dual targeting activates and redirects a patient’s existing T-cells to engage and eliminate target B-cells by releasing cytotoxic proteins into the B-cells. Mosunetuzumab has a structure similar to that of a natural human antibody in that it has two ‘Fab’ regions, but is different from naturally-occurring antibodies in that one ‘Fab’ region targets CD20 and the other ‘Fab’ region targets CD3.
A robust clinical development programme for mosunetuzumab is ongoing, investigating the molecule as a monotherapy and in combination with other medicines, for the treatment of people with CD20-positive B-cell non-Hodgkin lymphomas, including follicular lymphoma and diffuse large B-cell lymphoma, and other blood cancers.
Tafasitamab: Incyte Corporation
Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP).
Follicular lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different Follicular lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Follicular lymphoma
There are approx. 50+ key companies which are developing the therapies for Follicular lymphoma. The companies which have their Follicular lymphoma drug candidates in the most advanced stage, i.e. phase III include, Genentech.
Phases
This report covers around 50+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Follicular lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Follicular lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Follicular lymphoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Follicular lymphoma drugs.
Follicular lymphoma Report Insights
- Follicular lymphoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Follicular lymphoma Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Follicular lymphoma drugs?
- How many Follicular lymphoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Follicular lymphoma?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Follicular lymphoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Follicular lymphoma and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Merck & Co
- Genentech
- Incyte Corporation
- Syndax Pharmaceuticals
- Dr Reddy’s Laboratories
- Novartis
- ADC Therapeutics
- Xynomic Pharmaceuticals
- Cho Pharma Inc.
- Janssen
- XEME Biopharma Inc.
- Shanghai Yingli Pharmaceutical
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Beijing Mabworks Biotech Co., Ltd.
- Archigen Biotech
- Hutchison Medipharma Limited
- Nordic Nanovector
- Xynomic Pharmaceuticals
- TG Therapeutics
- BeiGene
- Allogene Therapeutics
- MEI Pharma, Inc.
- Pfizer
- Innovent Biologics (Suzhou) Co. Ltd.
- Enterome
- AstraZeneca
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Takeda
- Bristol-Myers Squibb
- TCR2 Therapeutics
Key Products
- Pembrolizumab
- Mosunetuzumab
- Tafasitamab
- Entinostat
- DRL_RI
- Tisagenlecleucel
- Loncastuximab Tesirine
- Abexinostat
- CHO-H01
- Ibrutinib
- Oncoquest-L vaccine
- YY-20394
- TQ-B3525
- MIL62
- SAIT101
- HMPL-689
- Betalutin
- Abexinostat
- Ublituximab
- Zanubrutinib
- ALLO-501
- Zandelisib
- PF-06821497
- IBI376
- EO2463
- Acalabrutinib
- SHC014748M
- TAK-659
- Nivolumab
- TC 110
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/1e0ser
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900